Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Kirsten Meid, MPH, Steven J Cropper, Patrick Mostyn, Diane Warren, Claudia E. Paba-Prada, MD, Christopher Patterson, Guang Yang, PhD, Zachary Hunter, Janet Kunsman, NP, Sandra Kanan, NP, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 757.

https://doi.org/10.1182/blood.V122.21.757.757

Published: 2013

Journal Articles

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Guang Yang, PhD, Yang Cao, MD, Lian Xu, Zachary Hunter, Steven J Cropper, Patrick Mostyn, Kirsten Meid, MPH, Diane Warren, Christopher Patterson, Gaurav Varma, MSPH, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Janet Kunsman, NP, Irene M. Ghobrial, MD, Sandra Kanan, NP, Ranjana H. Advani, MD, Maria Lia Palomba, MD

Blood (2013) 122 (21): 251.

https://doi.org/10.1182/blood.V122.21.251.251

Published: 2013

Journal Articles

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Tiffany Poon, BS, Federico Campigotto, MS, Erica N Boswell, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Amanda Donovan, BS, Meghan Bagshaw, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Edie Weller, PhD, Timothy J. Murphy, MD, FACP, Jeffrey Matous, MD

Blood (2011) 118 (21): 2706.

https://doi.org/10.1182/blood.V118.21.2706.2706

Published: 2011

Journal Articles

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Ranjit Banwait, MA, Tiffany Poon, BS, Amanda Donovan, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Meghan Bagshaw, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Steven Treon, MD, PhD

Blood (2011) 118 (21): 2705.

https://doi.org/10.1182/blood.V118.21.2705.2705

Published: 2011

Journal Articles

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Abdel Kareem Azab, Bpharm, PhD, Phong Quang, BS, Jacob P. Laubach, MD, Amanda Donovan, BS, Meghan Bagshaw, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2011) 118 (21): 1874.

https://doi.org/10.1182/blood.V118.21.1874.1874

Published: 2011

Journal Articles

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Irene Ghobrial, MD, Abdel Kareem A. Azab, PhD, BSPharm, Jacob P. Laubach, MD, MPP, Ranjit Banwait, Meghan Rourke, Phong Quang, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Amy Sam, Eric Still, Brittany Morgan, Kenneth C. Anderson, Paul G Richardson

Blood (2010) 116 (21): 1943.

https://doi.org/10.1182/blood.V116.21.1943.1943

Published: 2010

Journal Articles

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene Ghobrial, MD, Tiffany Poon, BS, Meghan Rourke, Stacey Chuma, BSN, Janet Kunsman, NP, Ranjit Banwait, Amy Sam, Diane Warren, Kenneth C. Anderson, Paul Richardson, M.D., Ph.D., Steven P. Treon, MD, PhD, Jeffrey Matous, MD

Blood (2010) 116 (21): 3952.

https://doi.org/10.1182/blood.V116.21.3952.3952

Published: 2010

Journal Articles

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

Blood (2010) 116 (21): 990.

https://doi.org/10.1182/blood.V116.21.990.990

Published: 2010

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

Irene M. Ghobrial, M.D., Ravi Vij, MD, Nikhil C. Munshi, Robert L Schlossman, M.D., Ph.D., Jacob Laubach, Erica L. Campagnaro, MD, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, NP, Akari M. Dollard, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D.

Blood (2009) 114 (22): 748.

https://doi.org/10.1182/blood.V114.22.748.748

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Fangxin Hong, PhD, Swaminathan Padmanabhan, MD, Ashraf Z. Badros, MD, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Edie Weller, PhD, Jeffrey Matous

Blood (2009) 114 (22): 2727.

https://doi.org/10.1182/blood.V114.22.2727.2727

Published: 2009

Journal Articles

Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM).

Xavier Leleu, Renee Leduc, Meghan Rourke, Stacey Chuma, Amy Sam, Brianna Harris, Janet Kunsman, NP, Irene M. Ghobrial, M.D.

Blood (2009) 114 (22): 3952.

https://doi.org/10.1182/blood.V114.22.3952.3952

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Swaminathan Padmanabhan, Ashraf Z. Badros, MD, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Jeffrey Matous

Blood (2009) 114 (22): 3752.

https://doi.org/10.1182/blood.V114.22.3752.3752

Published: 2009

NARROW

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM).

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only